_________________________________________________________________________________________________________________________
device manufacturing sector.“ We work in a heavily regulated industry and that’ s how it should be; our products are used in people’ s bodies to repair and heal, and we take that responsibility very seriously,” Stephen shares.“ Like all companies in the medical and pharmaceutical fields, we have a defined quality management system, subject to external audit, that sits at the centre of everything we do to ensure compliance.
“ However, I believe culture also plays an important role in compliance, as people must feel safe and comfortable to raise concerns or risks at any time. That starts with educating employees, connecting them with the work they do and how it matters to the end patient.”
Aside from operational transformation at the Keele facility, Biocomposites is constantly creating the next generation of products. Internal sales and marketing input, along with people from within the surgical community, shape the company’ s research and development( R & D) pipeline, which is currently in clinical development.“ We have some tremendously exciting and disruptive products in clinical development, and I’ m quietly confident we’ ll start to see them come to market over the next two-to-four years,” Stephen confirms.“ Although the US is already a core distribution market, our product pipeline is geared towards the specific needs of our US customers.”
286